Characteristics of Real‐World Metastatic Non‐Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval

BACKGROUND. Evidence from cancer clinical trials can be difficult to generalize to real‐world patient populations, but can be complemented by real‐world evidence to optimize personalization of care. Further, real‐world usage patterns of programmed cell death protein 1 (PD‐1) inhibitors following app...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncologist
Hoofdauteurs: Khozin, Sean, Abernethy, Amy P., Nussbaum, Nathan C., Zhi, Jizu, Curtis, Melissa D., Tucker, Melisa, Lee, Shannon E., Light, David E., Gossai, Anala, Sorg, Rachael A., Torres, Aracelis Z., Patel, Payal, Blumenthal, Gideon Michael, Pazdur, Richard
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: AlphaMed Press 2018
Onderwerpen:
Lung Cancer
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5905694/
https://ncbi.nlm.nih.gov/pubmed/29317551
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0353
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items